Kamal K. Abbi
Expertise in
30
conditions

Dr. Kamal K. Abbi

Internal Medicine | Oncology
3501 Ludington Street, 
Escanaba, MI 
On Staff At
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
30
conditions
3501 Ludington Street, 
Escanaba, MI 

Overview

Kamal Abbi is an Internal Medicine specialist and an Oncologist in Escanaba, Michigan. Dr. Abbi is highly rated in 30 conditions, according to our data. His top areas of expertise are Lung Cancer, Lymphofollicular Hyperplasia, Acute Monoblastic Leukemia (AmoL), Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 14 peer reviewed articles and participating in 26 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Government Medical College, Amritsar, No Value Specified, 2004

Residency

Penn State Milton S. Hershey Medical Center, Internal Medicine, 2011

Specialties

Internal Medicine
Oncology

Licenses

Internal Medicine in WI

Board Certifications

American Board Of Internal Medicine

Fellowships

University of Toledo Medical Center, Medical Oncology, 2013

Hospital Affiliations

Ascension Ne Wisconsin - St Elizabeth Campus
Osf St Francis Hospital And Medical Group
Schoolcraft Memorial Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

OSF HealthCare Daniel J. Kobasic Cancer Clinic
3501 Ludington Street, Escanaba, MI 49829

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Enrollment Status: Recruiting
Publish Date: February 04, 2026
Intervention Type: Procedure, Other
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Other, Drug
Study Drugs: Oxaliplatin, Duloxetine Hydrochloride, Duloxetine
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
View 8 Less Clinical Trials

14 Total Publications

Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft.
Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft.
Journal: Bone marrow transplantation
Published: July 26, 2019
Similar Doctors
Expertise in
59
conditions
Dr. Gustavo Morel
Oncology
Expertise in
59
conditions
Dr. Gustavo Morel
Oncology

Marshfield Medical Center-Dickinson Cancer Center

1721 S Stephenson Ave Ste 100, 
Iron Mountain, MI 
 (100.9 miles away)
906-776-5890
Languages Spoken:
English
See accepted insurances

Gustavo Morel is an Oncologist in Iron Mountain, Michigan. Dr. Morel is highly rated in 59 conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Adult Immune Thrombocytopenia, Philadelphia-Negative Chronic Myeloid Leukemia, and Chronic Myelogenous Leukemia (CML).

Anthony J. Jaslowski
Expertise in
51
conditions
Dr. Anthony J. Jaslowski
Hematology | Oncology | Internal Medicine
Expertise in
51
conditions
Dr. Anthony J. Jaslowski
Hematology | Oncology | Internal Medicine

OSF HealthCare Daniel J. Kobasic Cancer Clinic

3501 Ludington Street, 
Escanaba, MI 
 (97.3 miles away)
906-233-4140
Languages Spoken:
English
See accepted insurances

Anthony Jaslowski is a Hematologist and an Internal Medicine provider in Escanaba, Michigan. Dr. Jaslowski is highly rated in 51 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Colorectal Cancer, Bone Marrow Aspiration, and Myringotomy.

Brian L. Burnette
Expertise in
42
conditions
Dr. Brian L. Burnette
Hematology | Oncology
Expertise in
42
conditions
Dr. Brian L. Burnette
Hematology | Oncology

OSF HealthCare Daniel J. Kobasic Cancer Clinic

3501 Ludington Street, 
Escanaba, MI 
 (97.3 miles away)
906-233-4140
Languages Spoken:
English
See accepted insurances

Brian Burnette is a Hematologist and an Oncologist in Escanaba, Michigan. Dr. Burnette is highly rated in 42 conditions, according to our data. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Familial Colorectal Cancer, Colorectal Cancer, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Kamal K. Abbi

How do I make an appointment with Dr. Kamal K. Abbi?

You can book an appointment with Dr. Kamal K. Abbi by calling their office at 906-233-4140. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kamal K. Abbi a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kamal K. Abbi is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kamal K. Abbi specialize in?

While Dr. Kamal K. Abbi is a Internal Medicine, they have specific expertise in Lung Cancer, Lymphofollicular Hyperplasia, and Acute Monoblastic Leukemia (AmoL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Kamal K. Abbi participate in research or clinical trials?

Yes. Dr. Kamal K. Abbi has published 14 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Kamal K. Abbi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kamal K. Abbi accept my insurance?

Dr. Kamal K. Abbi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 906-233-4140 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Abbi's expertise for a condition
ConditionClose
    View All 26 Advanced Conditions
    View All 130 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile